4.5 Article

Protein-protein interaction investigated by steered molecular dynamics: The TCR-pMHC complex

期刊

BIOPHYSICAL JOURNAL
卷 95, 期 8, 页码 3575-3590

出版社

CELL PRESS
DOI: 10.1529/biophysj.108.131383

关键词

-

向作者/读者索取更多资源

We present a novel steered molecular dynamics scheme to induce the dissociation of large protein-protein complexes. We apply this scheme to study the interaction of a T cell receptor (TCR) with a major histocompatibility complex (MHC) presenting a peptide (p). Two TCR-pMHC complexes are considered, which only differ by the mutation of a single amino acid on the peptide; one is a strong agonist that produces T cell activation in vivo, while the other is an antagonist. We investigate the interaction mechanism from a large number of unbinding trajectories by analyzing van der Waals and electrostatic interactions and by computing energy changes in proteins and solvent. In addition, dissociation potentials of mean force are calculated with the Jarzynski identity, using an averaging method developed for our steering scheme. We analyze the convergence of the Jarzynski exponential average, which is hampered by the large amount of dissipative work involved and the complexity of the system. The resulting dissociation free energies largely underestimate experimental values, but the simulations are able to clearly differentiate between wild-type and mutated TCR-pMHC and give insights into the dissociation mechanism.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)

Markus Joerger, Yannis Metaxas, Khalil Zaman, Olivier Michielin, Nicolas Mach, Adrienne Bettini, Andreas M. Schmitt, Nathan Cantoni, Clemens B. Caspar, Sonja Stettler, Roma Malval, Miklos Pless, Christian Britschgi, Christoph Renner, Dieter Koeberle, Jessica D. Schulz, Christoph Kopp, Stefanie Hayoz, Anastasios Stathis, Roger von Moos

Summary: The characterization of clinical outcomes and prognostic factors in COVID-19-infected cancer patients is important. The study found that COVID-19 severity and mortality remained high in cancer patients in Switzerland, which has a decentralized, high-quality, universal-access health care system. Age, disease type, intensive care unit admission, and oxygen requirement were identified as independent negative prognostic factors for death from COVID-19.

CANCERS (2022)

Article Oncology

Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening

Katya Nardou, Michael Nicolas, Fabien Kuttler, Katarina Cisarova, Elifnaz Celik, Mathieu Quinodoz, Nicolo Riggi, Olivier Michielin, Carlo Rivolta, Gerardo Turcatti, Alexandre Pierre Moulin

Summary: Using a high throughput drug screening assay, this study evaluated the sensitivity of conjunctival melanoma cells to various inhibitors and found that cell cycle inhibition showed sensitivity in all cell lines, especially with polo-like inhibitors. Additionally, the response to MAPK pathway inhibition was better in the presence of BRAF(V600E) mutations, while the response to PI3k/mTOR inhibition was better in the presence of NRAS(Q61L) mutation. The study uncovers new vulnerabilities in conjunctival melanoma and expands therapeutic options for this tumor.

CANCERS (2022)

Article Oncology

COVID-19 in patients with cancer: first report of the ESMO international registry-based, cohort study (ESMO-CoCARE)

L. Castelo-Branco, Z. Tsourti, S. Gennatas, J. Rogado, M. Sekacheva, D. Vinal, R. Lee, A. Croitoru, M. Vitorino, S. Khallaf, S. Susnjar, W. Soewoto, A. Cardena, M. Djerouni, M. Rossi, T. Alonso-Gordoa, C. Ngelangel, J. G. Whisenant, T. K. Choueiri, G. Dimopoulou, S. Pradervand, D. Arnold, K. Harrington, O. Michielin, U. Dafni, G. Pentheroudakis, S. Peters, E. Romano

Summary: This study aimed to investigate the natural history, management, and outcomes of cancer patients infected with COVID-19. The study found that factors such as sex, age, cancer stage, body mass index, and comorbidities were associated with the severity and prognosis of COVID-19 in cancer patients.

ESMO OPEN (2022)

Article Oncology

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Rebecca J. Lee, Oskar Wysocki, Cong Zhou, Rohan Shotton, Ann Tivey, Louise Lever, Joshua Woodcock, Laurence Albiges, Angelos Angelakas, Dirk Arnold, Theingi Aung, Kathryn Banfill, Mark Baxter, Fabrice Barlesi, Arnaud Bayle, Benjamin Besse, Talvinder Bhogal, Hayley Boyce, Fiona Britton, Antonio Calles, Luis Castelo-Branco, Ellen Copson, Adina E. Croitoru, Sourbha S. Dani, Elena Dickens, Leonie Eastlake, Paul Fitzpatrick, Stephanie Foulon, Henrik Frederiksen, Hannah Frost, Sarju Ganatra, Spyridon Gennatas, Andreas Glenthoj, Fabio Gomes, Donna M. Graham, Christina Hague, Kevin Harrington, Michelle Harrison, Laura Horsley, Richard Hoskins, Prerana Huddar, Zoe Hudson, Lasse H. Jakobsen, Nalinie Joharatnam-Hogan, Sam Khan, Umair T. Khan, Khurum Khan, Christophe Massard, Alec Maynard, Hayley McKenzie, Olivier Michielin, Anne C. Mosenthal, Berta Obispo, Rushin Patel, George Pentheroudakis, Solange Peters, Kimberly Rieger-Christ, Timothy Robinson, Jacobo Rogado, Emanuela Romano, Michael Rowe, Marina Sekacheva, Roseleen Sheehan, Julie Stevenson, Alexander Stockdale, Anne Thomas, Lance Turtle, David Vinal, Jamie Weaver, Sophie Williams, Caroline Wilson, Carlo Palmieri, Donal Landers, Timothy Cooksley, Caroline Dive, Andre Freitas, Anne C. Armstrong

Summary: The study aimed to develop a decision support tool to assist in hospital admission decisions and predict the severity of COVID-19 in cancer patients. The results showed that the CORONET model could effectively predict the need for hospital admission and the severity of the disease, and it was validated in healthcare systems worldwide.

JCO CLINICAL CANCER INFORMATICS (2022)

Article Oncology

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

Claus Garbe, Ulrike Keim, Teresa Amaral, Carola Berking, Thomas K. Eigentler, Lukas Flatz, Anja Gesierich, Ulrike Leiter, Rudolf Stadler, Cord Sunderkotter, Thomas Tuting, Jochen Utikal, Uwe Wollina, Lisa Zimmer, Christos C. Zouboulis, Paolo A. Ascierto, Alexander M. M. Eggermont, Jean-Jacques Grob, Axel Hauschild, Lidija Kandolf Sekulovic, Georgina Long, Jason J. Luke, Olivier Michielin, Ketty Peris, Dirk Schadendorf, John M. Kirkwood, Paul C. Lorigan

Summary: This study evaluates the survival probabilities of patients with stage I and II melanoma and finds that the melanoma-specific survival rates in the two cohorts are less favorable compared to the published AJCCv8 data.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Editorial Material Radiology, Nuclear Medicine & Medical Imaging

Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18F-FDG PET/CT and Confirmed by Biopsy

Nathalie Testart Dardel, Elsa Isenborghs, Massimo Valerio, Olivier Michielin, Niklaus Schaefer

Summary: This case demonstrates an unusual presentation of melanoma metastasis in the right seminal vesicle, detected by F-18-FDG digital PET/CT. Histological analysis confirmed the diagnosis and the patient received stereotactic radiation therapy. The study highlights the excellent performance of state-of-the-art digital PET/CT and emphasizes the importance of a multidisciplinary approach in the treatment and follow-up of melanoma patients.

CLINICAL NUCLEAR MEDICINE (2023)

Article Oncology

Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma

Bianca Gautron Moura, Camille L. Gerard, Nathalie Testart, Marian Caikovski, Alexandre Wicky, Veronica Aedo-Lopez, Gregoire Berthod, Krisztian Homicsko, John O. Prior, Clarisse Dromain, Lana E. Kandalaft, Michel A. Cuendet, Olivier Michielin

Summary: In stage IV melanoma, the combination of ipilimumab and nivolumab significantly improves outcomes but has a major financial impact on healthcare. This study analyzes the costs associated with ipilimumab-nivolumab combination, focusing on immune-related adverse events (irAE). Surprisingly, toxicity costs are insignificant compared to the total treatment costs, and patients with higher toxicity grades have lower costs and better outcomes. These findings provide important information for clinicians and healthcare organizations making treatment decisions in immunotherapy.

CANCERS (2023)

Article Oncology

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient

Sandro Anchisi, Anita Wolfer, Bettina Bisig, Edoardo Missiglia, Amine Tiab, Ehab Mohamed Kamel, Olivier Michielin, George Coukos, Krisztian Homicsko

Summary: The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors, and BRAF/MEK combination has shown further improvements. BRAF inhibitor use has also been proposed in low-grade ovarian tumors.

CANCER BIOLOGY & THERAPY (2023)

Article Biochemistry & Molecular Biology

Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma

Fanny Seraphine Krebs, Bianca Moura, Edoardo Missiaglia, Veronica Aedo-Lopez, Olivier Michielin, Petros Tsantoulis, Bettina Bisig, Mounir Trimech, Vincent Zoete, Krisztian Homicsko

Summary: The development of targeted therapies for non-BRAF p.Val600-mutant melanomas remains challenging as Triple wildtype (TWT) melanomas lacking BRAF, NRAS, or NF1 mutations are heterogeneous in their genomic drivers. MAP2K1 mutations are enriched in BRAF-mutant melanomas and function as resistance mechanisms to BRAF inhibition. This case study illustrates the difficulties in combining MEK1 and CDK4/6 inhibitors in the presence of resistance to MEK inhibitor monotherapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Oncology

Interactive process mining of cancer treatment sequences with melanoma real-world data

Alexandre Wicky, Roberto Gatta, Sofiya Latifyan, Rita De Micheli, Camille Gerard, Sylvain Pradervand, Olivier Michielin, Michel A. Cuendet

Summary: The increasing availability of clinical real-world data (RWD) provides an opportunity to supplement evidence from randomized clinical trials and explore treatment outcomes in real-life conditions. Process mining is a suitable methodology for analyzing treatment paths and outcomes. In this study, an interactive application was implemented to compare treatment sequences based on overall survival, progression-free survival, and best overall response. The application was used to conduct a descriptive analysis of RWD in advanced melanoma patients and explore the outcomes of different treatment choices. Results showed long-term survival benefits from immune-checkpoint inhibitors rechallenge, suggesting potential implications for treatment guidelines.

FRONTIERS IN ONCOLOGY (2023)

Article Health Care Sciences & Services

Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial

Andre Manuel da Silva Lopes, Sara Colomer-Lahiguera, Celia Darnac, Stellio Giacomini, Sebastien Bugeia, Garance Gutknecht, Gilliosa Spurrier-Bernard, Michel Cuendet, Fanny Muet, Veronica Aedo-Lopez, Nuria Mederos, Olivier Michielin, Alfredo Addeo, Sofiya Latifyan, Manuela Eicher

Summary: This study aims to shorten the time between symptomatic immune-related adverse events (IrAEs) onset and clinician detection through remote patient monitoring and symptom management. The study plans to recruit 198 cancer patients receiving immune checkpoint inhibitors (ICIs) and randomize them into an intervention group and a control group. The results will make a significant impact on the routine care of patients treated with ICIs.

JMIR RESEARCH PROTOCOLS (2023)

Meeting Abstract Medicine, General & Internal

A model of care using patient-reported outcomes for remotely managing symptoms of cancer patients treated with immune checkpoint inhibitors

A. Da Silva Lopes, S. Colomer-Lahiguera, C. Darnac S. Giacomini, A. Wicky, S. Bugeia, G. Gutknecht, N. Mederos Alfonso, S. Latifyan, A. Addeo, O. Michielin, M. Eicher

SWISS MEDICAL WEEKLY (2022)

Correction Oncology

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies (vol 10, e003024, 2022)

O. Michielin, A. Lalani, C. Robert

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

暂无数据